DDInter1137 DDInter1592
Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma.[L8657,L8660,L8663,L8666,L8669] Medroxyprogesterone acetate was granted FDA approval on 18 June 1959.
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifampicin
Rifampicin {u} (Compound) resembles {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) resembles {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Musculoskeletal discomfort
Musculoskeletal discomfort {u} (Side Effect) is caused by {v} (Compound) Rifaximin
Rifaximin {u} (Compound) resembles {v} (Compound) Rifapentine
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rifabutin
Rifabutin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rifapentine
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)
Medroxyprogesterone acetate (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Rifapentine (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound) and Rifampicin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin (Compound) resembles Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifabutin (Compound) and Rifabutin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Rifaximin (Compound) and Rifaximin (Compound) resembles Rifapentine (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifapentine (Compound)